Compare WORX & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WORX | XRTX |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 4.4M |
| IPO Year | N/A | N/A |
| Metric | WORX | XRTX |
|---|---|---|
| Price | $0.24 | $0.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 61.6K |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,784,479.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $0.52 |
| 52 Week High | $2.16 | $1.79 |
| Indicator | WORX | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.35 | 50.44 |
| Support Level | $0.23 | $0.61 |
| Resistance Level | $0.25 | $0.67 |
| Average True Range (ATR) | 0.02 | 0.04 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 15.17 | 74.44 |
SCWorx Corp is a provider of data content and services related to the repair, normalization, and interoperability of information for healthcare providers, as well as big data analytics for the healthcare industry. Its software enables a healthcare provider to simplify and organize its data, allows the data to be utilized across multiple internal software applications, and provides the basis for sophisticated data analytics. The company has developed and markets healthcare information technology solutions and associated services to improve healthcare processes and information flow within hospitals and other healthcare facilities.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.